Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.30 |
| ▸ | CCR1 | P32246 | 1/20 | 0.30 |
| ▸ | CCR5 | P51681 | 1/20 | 0.30 |
| ▸ | CCR8 | P51685 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20326527 | 0.87 | NOS3 (0.38) | NOS3NOS1NOS2AOC3 | |
| SCHEMBL24138048 | 0.82 | ALDH1A1 (0.31) | CCR1CCR5CCR8 | |
| SCHEMBL15417760 | 0.78 | PDXK (0.39) | — | |
| SCHEMBL7124851 | 0.78 | NOS3 (0.38) | NOS3NOS1NOS2 | |
| SCHEMBL16310627 | 0.76 | LOXL2 (0.33) | NOS3NOS1NOS2 | |
| SCHEMBL21120989 | 0.76 | DAO (0.32) | NOS3NOS1NOS2 | |
| SCHEMBL15109313 | 0.76 | NOS3 (0.36) | NOS3NOS1NOS2 | |
| SCHEMBL24297744 | 0.76 | NOS3 (0.32) | NOS3NOS1NOS2 | |
| SCHEMBL18125581 | 0.76 | NOS3 (0.45) | NOS3NOS1NOS2 | |
| SCHEMBL14493554 | 0.76 | NOS3 (0.36) | NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11785966-B2 | Use of gamma-quaternary ammonium butyrate compound in preparation of an animal feed additive | Anipha Technologies Pty Ltd (AU) | 2023-10-17 | — | — | US | disclosed |
| EP-3692023-B1 | BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS | 1ST BIOTHERAPEUTICS INC (KR) | 2023-05-17 | — | — | EP | disclosed |
| US-20230128713-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND DIAGNOSTIC COMPOSITION INCLUDING THE ORGANOMETALLIC COMPOUND | SAMSUNG ELECTRONICS CO LTD (KR) | 2023-04-27 | — | — | US | disclosed |
| US-20220132889-A1 | USE OF GAMMA-QUATERNARY AMMONIUM BUTYRATE COMPOUND IN PREPARATION OF AN ANIMAL FEED ADDITIVE | PENG, Xianfeng (CN) | 2022-05-05 | — | — | US | disclosed |
| US-20120196845-A1 | QUINOLINONE-PYRAZOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2012-08-02 | — | — | US | disclosed |
| US-20030064989-A1 | Inhibitors of cell proliferation, angiogenesis, fertility, and muscle contraction | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2003-04-03 | — | — | US | disclosed |
| US-5262420-A | Phenylalkylpyridines | IDEMITSU KOSAN CO., LTD. (JP) | 1993-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128713-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND DIAGNOSTIC COMPOSITION INCLUDING THE ORGANOMETALLIC COMPOUND | ORC3, LEF1, OCIAD1 | NOS3 2270/4885NOS1 862/4885NOS2 2140/4885 |
| US-20030064989-A1 | Inhibitors of cell proliferation, angiogenesis, fertility, and muscle contraction | MYH10, MYLK, MKI67 | NOS3 416/4885NOS1 1076/4885NOS2 1820/4885 |
| US-20120196845-A1 | QUINOLINONE-PYRAZOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, OPRL1, CHRNA5 | NOS3 2934/4885NOS1 1548/4885NOS2 3022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.